Weekly Digest - September 2024

Weekly Digest - September 2024

11 Sep 2024: OS Therapies announces positive efficacy and safety data for ovarian cancer therapeutic candidate developed based on tunable antibody drug conjugate (tADC) platform using proprietary silicone linker platform in preclinical models

  • The folate receptor alpha targeting drug conjugate with hexa-silanol exatecan (FRA-H) showed strong efficacy in animal models of ovarian cancer
  • OST-tADC technology uses SiLinker™ for selective payload release within the tumor environment, aiming to enhance therapeutic effects while minimizing healthy cell damage
  • Animal model data showed that OST-tADC-FRA-H effectively reduced tumor growth compared to control treatments, with significant tumor size reductions and no adverse effects on body weight
  • The proof-of-concept study for FRA-H supports the development of multiple potential therapeutic candidates for further preclinical and clinical evaluation

For full story click here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home